Loading news...
Omnicell, Inc. (NASDAQ: OMCL - Get Free Report) has received an average rating of "Hold" from the eight ratings firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating on the company.
Investors interested in stocks from the Medical Info Systems sector have probably already heard of Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks presents investors with the better value opportunity right now?
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medical Info Systems rides AI and telehealth tailwinds, lifting DOCS, TXG and OMCL, but cyber risks and industry underperformance keep optimism in check.
Omnicell (NASDAQ: OMCL - Get Free Report) and Careview Communications (OTCMKTS:CRVW - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability. Risk and Volatility Omnicell has a beta of 0.77,
Omnicell (OMCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Investors interested in stocks from the Medical Info Systems sector have probably already heard of Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks presents investors with the better value opportunity right now?
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Release Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026.
6,106 shares were sold for a transaction value of $243,629 on Dec. 3, 2025. The sale represented 5.85% of direct holdings, reducing direct ownership to 98,282 shares (0.2122% of shares outstanding).
PAAS, OMCL and MDB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Dec. 16, 2025.
COF, QCRH, TNET, MDB and OMCL have been added to the Zacks Rank #1 (Strong Buy) List on Dec. 16, 2025.
Federated Hermes Inc. reduced its position in Omnicell, Inc. (NASDAQ: OMCL) by 20.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 594,944 shares of the company's stock after selling 151,555 shares during the period. Federated Hermes Inc. owned
Omnicell, Inc. (OMCL) Discusses Launch of Titan XT Enterprise Platform and Its Impact on Pharmacy Operations Transcript
Investors interested in Medical Info Systems stocks are likely familiar with Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks presents investors with the better value opportunity right now?
FORT WORTH, Texas--(BUSINESS WIRE)--Announcing Omnicell Titan XT, the Next Generation, Automated Dispensing System Designed to Empower Autonomous Medication Management.
OMCL's expanding SaaS pipeline, global push and solid solvency highlight growth potential despite rising competition.
Capital Fund Management S.A. grew its stake in shares of Omnicell, Inc. (NASDAQ: OMCL) by 97.1% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 44,713 shares of the company's stock after buying an additional 22,031 shares during the period. Capital Fund Management
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Host Innovation Update and Q&A Session at Upcoming ASHP Midyear Industry Trade Show.
The consensus price target hints at a 30.9% upside potential for Omnicell (OMCL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the Piper Sandler 37th Annual Healthcare Conference.